3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor Cancer
1
Advanced Malignant Solid Tumors
1
Interventions
Cyclophosphamide
6
Thiotepa
5
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Busulfan
4
tislelizumab
3
Melphalan
3
Carboplatin
3
tazemetostat
2
regorafenib
2
pembrolizumab
2
belinostat
2
Topotecan
2
Temozolomide
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mesna
2
Ifosfamide
2
Doxorubicin
2
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
pegylated granulocyte colony-stimulating factor
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
entinostat
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Clinical Trials, Phase II as Topic
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled